Adamis pharmaceuticals cleared to proceed with human studies of tempol for the treatment of covid-19

San diego, feb. 22, 2021 (globe newswire) --  adamis pharmaceuticals corporation (nasdaq: admp) ("company") announced today that the u.s. food and drug administration (“fda”) has completed the safety review of the company's investigational new drug (“ind”) application and has concluded that adamis may proceed with the proposed clinical investigation of tempol for the treatment of covid-19. the clearance to proceed follows the submission of an ind application to fda and a pre-ind meeting.
ADMP Ratings Summary
ADMP Quant Ranking